Biohaven Shares Plunge 17% After Failed Depression Drug Trial

Shares of Biohaven Ltd. (BHVN) experienced a significant decline of 17% in after-hours trading on December 24, 2025, following the announcement that its clinical trial for the depression drug BHV-7000 did not meet its primary endpoint. The mid-stage proof-of-concept study aimed at assessing the drug’s effectiveness in treating major depressive disorder revealed no significant reduction in depressive symptoms compared to a placebo over the six-week duration of the trial.

Despite the lack of overall efficacy, the company noted some promising trends in specific subgroups of participants, particularly those with more severe forms of depression. The trial also indicated that BHV-7000 was safe and well-tolerated, with most adverse events being mild or moderate and resolving spontaneously. However, in light of these results, Biohaven announced that it will not pursue further psychiatric clinical trials and will redirect its focus towards other therapeutic areas such as immunology, obesity, and epilepsy in 2026.

Broader Setbacks and Strategic Shifts

This latest setback is part of a challenging year for Biohaven. The company faced a setback in March when BHV-7000 failed to meet its primary endpoint in a pivotal Phase II/III clinical trial for bipolar disorder. Furthermore, last month, the U.S. Food and Drug Administration (FDA) declined to approve Biohaven’s drug Vyglxia for the treatment of Spinocerebellar ataxia, a neurodegenerative disorder that leads to motor control loss and brain atrophy. The FDA’s refusal was attributed to concerns regarding potential bias, design flaws, and the absence of pre-specified endpoints in the company’s studies.

In response to these challenges, Biohaven has initiated a strategic review of its portfolio. The company aims to concentrate on three late-stage clinical programs that have the most potential for generating value over the upcoming year. Additionally, it plans to implement a cost optimization strategy to achieve an approximate 60% reduction in annual direct research and development expenditures. This may involve pausing or delaying non-priority programs to extend its cash runway.

Market Reaction and Future Prospects

On social media platform Stocktwits, reactions from retail investors have largely remained in the ‘bearish’ category following the announcement, with message volume increasing from normal to high. One user characterized the disappointing update as “expected” but expressed optimism for the upcoming epilepsy trial, stating, “Good things are to come here.” Another user highlighted the potential of the company’s investigational obesity drug as an additional catalyst for future growth.

Despite the recent downturn, Biohaven’s stock has seen a dramatic decline of approximately 71% in 2025 and around 70% over the past year. As the company shifts its focus, investors and analysts will be closely monitoring its progress in epilepsy and obesity research, hoping for positive developments to counterbalance the recent setbacks.